1-苯基环丁基甲酸 | 37828-19-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-苯基环丁基甲酸
• 中文别名: 1-苯基环丁烷羧酸
• 英文名称: 1-(phenyl)cyclobutane-1-carboxylic acid
• 英文别名: 1-phenyl-cyclobutanecarboxylic acid；1-phenyl-1-cyclobutanecarboxylic acid；1-Phenylcyclobutanecarboxylic acid；1-phenylcyclobutane-1-carboxylic acid
• CAS: 37828-19-6
• 化学式: C₁₁H₁₂O₂
• mdl: MFCD00019262
• 分子量: 176.215
• InChiKey: JHZRNLRTNIDFKG-UHFFFAOYSA-N

物化性质

• 熔点：
  100-102℃
• 沸点：
  323.9±21.0 °C(Predicted)
• 密度：
  1.208±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.363
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2916399090
• 危险性防范说明：
  P280,P305+P351+P338,P310
• 危险性描述：
  H302,H315,H319,H332,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
1-Phenylcyclobutanecarboxylic acid
Product Name:
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
1-Phenylcyclobutanecarboxylic acid
Ingredient name:
CAS number: 37828-19-6

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C11H12O2
Molecular weight: 176.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-苯基环丁基甲酸 在 草酰氯 、 1-叔丁基-3-碘苯 、 N,N-二甲基甲酰胺 、 间氯过氧苯甲酸 作用下， 以 二氯甲烷 为溶剂， 反应 12.0h， 生成 1'-methoxyspiro[cyclobutane-1,3'-indolin]-2'-one
  参考文献：
  名称：

  一种有效的 3,3-二取代羟吲哚合成方法：芳基碘催化分子内 C-N 键氧化交叉偶联

  摘要：

  在此，我们报告了第一个通过有机催化氧化反应形成苯丙酰胺衍生物的分子内 C-N 键，得到 3,3-二取代的羟吲哚衍生物，产率高达 99%。该反应的高效率体现在无过渡金属的温和条件和以克规模进行反应的能力。同时，还研究了催化氧化转化途径的DFT计算。

  DOI：

  10.1021/acs.orglett.1c03224
• 作为产物：
  描述：

  2-methyl-5-(1-phenylcyclobutyl)furan 在 sodium periodate 、 水 、 ruthenium trichloride 作用下， 以 正庚烷 、 乙酸乙酯 为溶剂， 反应 18.08h， 以100%的产率得到1-苯基环丁基甲酸
  参考文献：
  名称：

  通过选择性呋喃氧化裂解短时间合成氧杂环丁烷和氮杂环丁烷3-芳基-3-羧酸衍生物。

  摘要：

  尽管四元环为药物化学提供了引人注目的理化性质，但它们仍然是未开发的基序。带有氧杂环丁烷，氮杂环丁烷和环丁烷的丙烯酸可以分两个步骤制备：从四元环醇底物进行的Friedel-Crafts催化反应，然后进行温和的氧化裂解。产品作为构建基块的适用性体现在其易于纯化和易于衍生化方面。实例包括杂芳族化合物和芳基三氟甲磺酸酯，以及氧杂环丁烷衍生的芬芬药物类似物和含有氮杂环丁烷氨基酸残基的新内啡肽衍生物。

  DOI：

  10.1021/acs.orglett.0c01214

文献信息

• [EN] 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE<br/>[FR] AGONISTES DE RÉCEPTEUR 5-HT2C ET COMPOSITIONS ET PROCÉDÉS D'UTILISATION
  申请人：ARENA PHARM INC

  公开号：WO2017023679A1

  公开（公告）日：2017-02-09

  Provided in some embodiments are compounds of Formula A, as defined herein, that modulate the activity of 5-HT2C receptor. Also provided in some embodiments are methods, such as, for weight management, inducing satiety, and decreasing food intake, and for preventing and treating obesity, antipsychotic-induced weight gain, type 2 diabetes, Prader-Willi syndrome, tobacco/nicotine dependence, drug addiction, alcohol addiction, pathological gambling, reward deficiency syndrome, and sex addiction), obsessive-compulsive spectrum disorders and impulse control disorders (including nail-biting and onychophagia), sleep disorders (including insomnia, fragmented sleep architecture, and disturbances of slow-wave sleep), urinary incontinence, psychiatric disorders (including schizophrenia, anorexia nervosa, and bulimia nervosa), Alzheimer disease, sexual dysfunction, erectile dysfunction, epilepsy, movement disorders (including parkinsonism and antipsychotic-induced movement disorder), hypertension, dyslipidemia, nonalcoholic fatty liver disease, obesity-related renal disease, and sleep apnea.

  在某些实施例中提供了一些符合本文所定义的A式化合物，其调节5-HT2C受体的活性。在某些实施例中还提供了一些方法，例如用于体重管理、诱导饱腹感、减少食物摄入，以及预防和治疗肥胖、抗精神病药物引起的体重增加、2型糖尿病、普拉德-威利综合征、烟草/尼古丁依赖、药物成瘾、酒精成瘾、病理性赌博、奖赏缺乏综合征和性成瘾，强迫症谱系障碍和冲动控制障碍（包括咬指甲和咬甲症），睡眠障碍（包括失眠、睡眠结构碎裂和慢波睡眠紊乱），尿失禁，精神障碍（包括精神分裂症、厌食症和暴食症），阿尔茨海默病，性功能障碍，勃起功能障碍，癫痫，运动障碍（包括帕金森病和抗精神病药物引起的运动障碍），高血压，血脂异常，非酒精性脂肪肝病，肥胖相关肾脏疾病和睡眠呼吸暂停症。
• Substituted alkanoic acids
  申请人：——

  公开号：US20040006056A1

  公开（公告）日：2004-01-08

  The invention is directed to physiologically active compounds of general formula (I): 1 wherein:- 2 represents (i) a saturated 3 to 6 membered carbocycle, optionally substituted by one or more alkyl groups, (ii) indanyl or (iii) a saturated 4 to 6 membered heterocyclic ring; R 1 represents R 3 Z 1 -Het- or R 4 N(R 5 )—C(═O)—NH—Ar 1 —; L 1 represents an —R 6 —R 7 — linkage; R 2 represents hydrogen, halogen, lower alkyl or lower alkoxy; L 2 represents an alkylene linkage; Y is carboxy or an acid bioisostere; and their corresponding N-oxides or prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their corresponding N-oxides or prodrugs. Such compounds have valuable pharmaceutical properties, in particular the ability to regulate the interaction of VCAM-1 and fibronectin with the integrin VLA-4 (&agr;4&bgr;1).

  该发明涉及一般式(I)的生理活性化合物： 1 其中：- 2 表示(i)饱和的3至6成员碳环，可选地由一个或多个烷基取代，(ii)吲哚基或(iii)饱和的4至6成员杂环环； R 1 表示R 3 Z 1 -Het-或R 4 N(R 5 )—C(═O)—NH—Ar 1 —； L 1 表示一个—R 6 —R 7 —连接； R 2 表示氢、卤素、低烷基或低烷氧基； L 2 表示一个烷基连接； Y为羧基或酸生物同位素； 以及这些化合物及其相应的N-氧化物或前药，以及这些化合物及其相应的N-氧化物或前药的药学上可接受的盐和溶剂。 这些化合物具有有价值的药理特性，特别是调节VCAM-1和纤维连接蛋白与整合素VLA-4(&agr;4&bgr;1)相互作用的能力。
• Monofluoromethyl‐Substituted Sulfonium Ylides: Electrophilic Monofluoromethylating Reagents with Broad Substrate Scopes
  作者：Yafei Liu、Long Lu、Qilong Shen

  DOI：10.1002/anie.201704175

  日期：2017.8.7

  Two electrophilic monofluoromethylating reagents, monofluoromethyl(phenyl)sulfonium bis(carbomethoxy)methylide (3 a) and monofluoromethyl(4‐nitrophenyl)sulfonium bis(carbomethoxy)methylide (3 b), and their reactions under mild conditions with a variety of nucleophiles, such as alcohols and malonate derivatives, sulfonic and carboxylic acids, phenols, amides, and N heteroarenes, are described. Mechanistic

  两种亲电单氟甲基化试剂，单氟甲基（苯基）ulf双（羰甲氧基）甲基化物（3a）和单氟甲基（4-硝基苯基）ulf双（羰甲氧基）甲基化物（3b），以及它们在温和条件下与各种亲核试剂的反应作为醇和丙二酸酯的衍生物，描述了磺酸和羧酸，酚，酰胺和N杂芳烃。用氘化试剂[D 2 ] 3 a / [D 2 ] 3 b进行的机理研究表明，这些单氟甲基化反应是通过亲电取代途径进行的。
• [EN] 1,1-DISUBSTITUTED CYCLOALKYL DERIVATIVES AS FACTOR XA INHIBITORS<br/>[FR] DERIVES CYCLOALKYLES 1,1-DISUBSTITUES UTILISES EN TANT QU'INHIBITEURS DU FACTEUR XA
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2003099276A1

  公开（公告）日：2003-12-04

  The present application describes 1,1-disubstituted cycloalkyl compounds and derivatives thereof, or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of factor Xa.

  本申请描述了1,1-二取代环烷基化合物及其衍生物，或其药用可接受的盐形式，这些化合物对于Xa因子的抑制剂具有用处。
• Systematic Investigation of Halogen Bonding in Protein–Ligand Interactions
  作者：Leo A. Hardegger、Bernd Kuhn、Beat Spinnler、Lilli Anselm、Robert Ecabert、Martine Stihle、Bernard Gsell、Ralf Thoma、Joachim Diez、Jörg Benz、Jean‐Marc Plancher、Guido Hartmann、David W. Banner、Wolfgang Haap、François Diederich

  DOI：10.1002/anie.201006781

  日期：2011.1.3

  Halogen bonding triggers activity: Increasing binding affinity was observed for a series of covalent human Cathepsin L inhibitors by exchanging an aryl ring H atom with Cl, Br, and I, which undergo halogen bonding with the CO group of Gly61 in the S3 pocket of the enzyme. Fluorine, in contrast, strongly avoids halogen bonding (see scheme). The strong distance and angle dependence of halogen bonding

  卤素键触发活性：通过将芳环H原子与Cl，Br和I交换，可以观察到一系列共价的人组织蛋白酶L抑制剂的结合亲和力增加，Cl，Br和I与S3口袋中的Gly61的CO基团进行卤素键合酶。相反，氟强烈避免卤素键（参见方案）。卤素键的强距离和角度依赖性已被证实适用于生物系统。